Healthcare stocks take a hit after Trump order

Amy Baxter | | Health Exec | Policy & Regulations
Stocks

Healthcare stocks are reeling following an executive order from President Trump that would give HHS the ability to require hospitals and health insurance companies to provide patients with prices for healthcare services based on negotiated rates. The idea is to make healthcare more “shoppable,” but healthcare providers are not enthused by the idea.

Stocks of major healthcare insurers, including UnitedHealth Group, Humana, Cigna and Anthem all fell in the aftermath of the news, according to Zacks. Hospital stocks, including Community Health Systems and Tenet Healthcare, took bigger hits, with drops of 5.17% and 2.57%, respectively, on Tuesday.

The administration has already finalized a new requirement to make drugmakers publish the list prices of pharmaceuticals in TV advertisements, but most patients with health insurance end up paying negotiated prices.

See the full story below:

Healthcare Tumbles on Trump's Price Disclosure Order

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.